DC
VOR icon

Diametric Capital’s Vor Biopharma VOR Stock Holding History

Diametric Capital’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$180K Buy
+10,070
New +$142K 0.05% 391
2023
Q2 		– Sell
-645
Closed -$69.4K – 469
2023
Q1 		$69.4K Buy
+645
New +$71.5K 0.03% 291

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Diametric Capital's VOR Position: Q1 2026 in Review

Diametric Capital opened a new position in Vor Biopharma (VOR) in Q1 2026: 10,070 shares worth $180K. The stake represents 0.05% of the portfolio and ranks #391 among its holdings. This is a return to the name: Diametric Capital previously reported a position in VOR as recently as Q1 2023.

Diametric Capital first reported a position in VOR in Q1 2023 and has held it in 2 quarters since. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

  • Diametric Capital held 10,070 shares of Vor Biopharma worth $180K as of Q1 2026.
  • Vor Biopharma was a new Diametric Capital position in Q1 2026.
  • Vor Biopharma made up 0.05% of Diametric Capital's portfolio in Q1 2026, its #391 holding.
  • Diametric Capital first reported a position in Vor Biopharma in Q1 2023 and has held it in 2 quarters since.
  • 80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Diametric Capital's 13F filing for Q1 2026, filed 15 May 2026.